LSV Asset Management Invests $5.37 Million in LivaNova PLC (NASDAQ:LIVN)

LSV Asset Management bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 115,900 shares of the company's stock, valued at approximately $5,367,000. LSV Asset Management owned about 0.21% of LivaNova at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. F M Investments LLC purchased a new stake in shares of LivaNova in the 4th quarter worth $2,687,000. Martingale Asset Management L P grew its holdings in LivaNova by 109.3% during the fourth quarter. Martingale Asset Management L P now owns 24,561 shares of the company's stock valued at $1,137,000 after purchasing an additional 12,826 shares during the period. Renaissance Technologies LLC increased its position in LivaNova by 9.2% in the fourth quarter. Renaissance Technologies LLC now owns 112,594 shares of the company's stock worth $5,214,000 after buying an additional 9,500 shares in the last quarter. Invesco Ltd. raised its stake in shares of LivaNova by 0.6% in the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company's stock worth $5,158,000 after buying an additional 667 shares during the period. Finally, Federated Hermes Inc. lifted its position in shares of LivaNova by 1.3% during the 4th quarter. Federated Hermes Inc. now owns 142,893 shares of the company's stock valued at $6,617,000 after buying an additional 1,823 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on LIVN shares. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Barclays dropped their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday, March 7th. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group dropped their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $61.17.

LivaNova Price Performance

Shares of LivaNova stock traded up $0.51 during trading on Friday, reaching $35.58. 614,570 shares of the stock traded hands, compared to its average volume of 627,229. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The business has a fifty day simple moving average of $40.08 and a two-hundred day simple moving average of $46.76. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of 84.71 and a beta of 0.90.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.